Stay updated with breaking news from Equity Holders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical activity in relapsed/refractory multiple myeloma (r/r MM)
Dufry International AG / Key word(s): Miscellaneous Dufry with strong recovery reporting Organic Growth of 53.2% and Adjusted Operating Profit of CHF 374.9 million 08-March-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the con...
Dufry International AG / Key word(s): Miscellaneous Dufry with strong recovery reporting Organic Growth of 53.2% and Adjusted Operating Profit of CHF 374.9 million 08-March-2022 / 07:00 CET/CEST Release
08.03.2022 - Dufry International AG / Key word(s): Miscellaneous Dufry with strong recovery reporting Organic Growth of 53.2% and Adjusted Operating Profit of CHF 374.9 million 08-March-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 ...
Igraine Plc - Interim Results to 30 June 2021 PR Newswire London, December 22 THE DIRECTORS OF IGRAINE PLC CONSIDER THIS ANNOUNCEMENT TO CONTAIN INSIDE INFORMATION FOR THE